[go: up one dir, main page]

WO2007044375A3 - Pth formulations and methods of use - Google Patents

Pth formulations and methods of use Download PDF

Info

Publication number
WO2007044375A3
WO2007044375A3 PCT/US2006/038735 US2006038735W WO2007044375A3 WO 2007044375 A3 WO2007044375 A3 WO 2007044375A3 US 2006038735 W US2006038735 W US 2006038735W WO 2007044375 A3 WO2007044375 A3 WO 2007044375A3
Authority
WO
WIPO (PCT)
Prior art keywords
pth
methods
formulation
mammal
treating osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/038735
Other languages
French (fr)
Other versions
WO2007044375A2 (en
Inventor
Henry R Costantino
Steven C Quay
Michael V Templin
Ching-Yuan Li
Anthony P Sileno
Kristin B Prinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/246,450 external-priority patent/US20060052306A1/en
Priority claimed from US11/246,406 external-priority patent/US20060052305A1/en
Priority claimed from US11/347,551 external-priority patent/US20060127320A1/en
Priority claimed from US11/390,940 external-priority patent/US20060189533A1/en
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of WO2007044375A2 publication Critical patent/WO2007044375A2/en
Publication of WO2007044375A3 publication Critical patent/WO2007044375A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

What is described is an aqueous pharmaceutical formulation of PTH, comprising a therapeutically effective amount of PTH(l-34) and one or more excipients selected from the group consisting of a solubilizing agent, a chelating agent, one or more polyols, and a nonionic surface active agent, a method of using such formulation for treating osteoporosis in a mammal by intranasal administration, and use of PTH(I -34) in the manufacture of such formulation for treating osteoporosis in a mammal.
PCT/US2006/038735 2005-10-06 2006-10-03 Pth formulations and methods of use Ceased WO2007044375A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US11/246,406 2005-10-06
US11/246,450 2005-10-06
US11/246,450 US20060052306A1 (en) 2004-05-10 2005-10-06 GRAS composition for enhanced mucosal delivery of parathyroid hormone
US11/246,406 US20060052305A1 (en) 2004-05-10 2005-10-06 Method of treating osteoporosis using intranasal parathyroid hormone
US73826405P 2005-11-17 2005-11-17
US60/738,264 2005-11-17
US11/347,551 US20060127320A1 (en) 2004-05-10 2006-02-03 Method of delivering parathyroid hormone to a human
US11/347,551 2006-02-03
US11/390,940 US20060189533A1 (en) 2004-05-10 2006-03-27 Stable pharmaceutical dosage forms of teriparatide
US11/390,940 2006-03-27
US80676006P 2006-07-07 2006-07-07
US60/806,760 2006-07-07

Publications (2)

Publication Number Publication Date
WO2007044375A2 WO2007044375A2 (en) 2007-04-19
WO2007044375A3 true WO2007044375A3 (en) 2007-12-06

Family

ID=37758552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038735 Ceased WO2007044375A2 (en) 2005-10-06 2006-10-03 Pth formulations and methods of use

Country Status (1)

Country Link
WO (1) WO2007044375A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
RS60101B1 (en) 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
TR201711271T4 (en) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Treatments for Gastrointestinal Disorders
PL2603232T3 (en) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatment of gastrointestinal disorders
EP2903619B1 (en) * 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
WO2014143453A1 (en) * 2013-03-15 2014-09-18 Henkin Robert I Phosphodiesterase inhibitor treatment
CN106233141B (en) 2014-02-18 2018-08-21 罗伯特·I·汉金 Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN110996988A (en) * 2017-09-22 2020-04-10 旭化成制药株式会社 Liquid pharmaceutical composition containing teriparatide with excellent stability

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578567A (en) * 1990-09-20 1996-11-26 Sandoz Ltd. Nasal pharmaceutical composition
EP0747054A2 (en) * 1995-06-06 1996-12-11 Eli Lilly And Company Methods for minimizing bone loss
EP0878201A1 (en) * 1996-02-01 1998-11-18 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for thrombocytopenia
US6416503B1 (en) * 1993-09-22 2002-07-09 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoreses
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
WO2005115441A2 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578567A (en) * 1990-09-20 1996-11-26 Sandoz Ltd. Nasal pharmaceutical composition
US6416503B1 (en) * 1993-09-22 2002-07-09 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoreses
EP0747054A2 (en) * 1995-06-06 1996-12-11 Eli Lilly And Company Methods for minimizing bone loss
EP0878201A1 (en) * 1996-02-01 1998-11-18 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for thrombocytopenia
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
WO2005115441A2 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide

Also Published As

Publication number Publication date
WO2007044375A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2007044375A3 (en) Pth formulations and methods of use
TNSN08365A1 (en) Sustained release pharmaceutical composition on the basis of release system comprising an acid-soluble polymer and a ph-dependent polymer
WO2005115441A3 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
MX2008000099A (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof.
MY151457A (en) Topical formulation and uses thereof
WO2005021022A3 (en) Stable formulations of peptides
SE0300831D0 (en) New formulations and use therof
WO2002009690A8 (en) Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
WO2007022535A3 (en) Prodrugs of active agents
WO2009071219A3 (en) Oral dispersable tablet
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
BR0313627A (en) Pharmaceutical formulations, processes for the preparation of pharmaceutical formulations and method for treating pain
WO2007067964A3 (en) Mucosal delivery of stabilized formulations of exendin
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
HUP0401811A2 (en) Medicinal composition improved in solubility in water and process for its preparation
WO2008130395A3 (en) Desferrithiocin analogue actinide decorporation agents
WO2004069138A3 (en) Pharmaceutical formulation
NO20061625L (en) Treatment and / or prevention of urinary incontinence using prodrugs of gaba analogues
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2007039760A3 (en) Use of oligouronates for treating mucus hyperviscosity
WO2007010400A3 (en) Gastroretentive formulations and manufacturing process thereof
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007143382A3 (en) Oral liquid loratadine formulations and methods
ATE472251T1 (en) PROCESS FOR FRUIT THINNING

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06825431

Country of ref document: EP

Kind code of ref document: A2